PortfoliosLab logo

Blueprint Medicines Corporation (BPMC)

Equity · Currency in USD · Last updated Mar 26, 2023

Share Price Chart

Loading data...


The chart shows the growth of $10,000 invested in Blueprint Medicines Corporation in Oct 2022 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $23,042 for a total return of roughly 130.42%. All prices are adjusted for splits and dividends.

BPMC (Blueprint Medicines Corporation)
Benchmark (^GSPC)

S&P 500

Compare to other instruments

Search for stocks, ETFs, and funds to compare with BPMC

Blueprint Medicines Corporation


Blueprint Medicines Corporation had a return of -0.75% year-to-date (YTD) and -32.46% in the last 12 months. Over the past 10 years, Blueprint Medicines Corporation had an annualized return of 11.16%, outperforming the S&P 500 benchmark which had an annualized return of 8.50%.

1 month-0.07%-0.66%
6 months-35.20%5.67%
1 year-32.46%-10.89%
5 years (annualized)-14.40%8.95%
10 years (annualized)11.16%8.50%

Monthly Returns Heatmap


Sharpe Ratio Chart

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Blueprint Medicines Corporation Sharpe ratio is -0.53. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.

The chart below displays rolling 12-month Sharpe Ratio.

BPMC (Blueprint Medicines Corporation)
Benchmark (^GSPC)

Dividend History

Blueprint Medicines Corporation doesn't pay dividends

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.

BPMC (Blueprint Medicines Corporation)
Benchmark (^GSPC)

Worst Drawdowns

The table below shows the maximum drawdowns of the Blueprint Medicines Corporation. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Blueprint Medicines Corporation is 69.50%, recorded on Feb 24, 2023. The portfolio has not recovered from it yet.



To Bottom


To Recover



-69.5%Dec 24, 2020545Feb 24, 2023
-62.86%Jun 19, 2015161Feb 8, 2016198Nov 17, 2016359
-55.74%Mar 16, 2018195Dec 21, 2018459Oct 19, 2020654
-32.79%Nov 25, 201613Dec 13, 201659Mar 10, 201772
-27.1%May 2, 201720May 30, 201718Jun 23, 201738
-24.32%Jul 6, 201732Aug 18, 201718Sep 14, 201750
-18.05%Dec 12, 20176Dec 19, 201745Feb 26, 201851
-13.61%Nov 6, 20177Nov 14, 201711Nov 30, 201718
-10.67%Oct 30, 202014Nov 18, 20206Nov 27, 202020
-10.62%Dec 1, 20173Dec 5, 20174Dec 11, 20177

Volatility Chart

Current Blueprint Medicines Corporation volatility is 43.30%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.

BPMC (Blueprint Medicines Corporation)
Benchmark (^GSPC)